Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9269 Tagraxofusp-erzs Elzonris 10mcg Immunotherapy Recombinant Fusion Protein IL3/CD123 No 2018 Oct 1, 2019 In Use
NA Talazoparib Talzenna 0.25mg, 1mg Chemotherapy Enzyme Inhibitor PARP Yes 2018 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan 1, 2017 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Apr 1, 2016 In Use
NA Purixan Purixan 20mg Chemotherapy Antimetabolite Purine Yes 2014 In Use
J9330 Temsirolimus Torisel 1 mg Chemotherapy Enzyme Inhibitor mTOR No 2007 Jan 1, 2009 In Use
NA ixazomib Ninlaro 3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA ixazomib Ninlaro 2.3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA ixazomib Ninlaro 4 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
J2354 octreotide sandostatin 25 mcg Hormonal Therapy Somatostatin Analog No 1998 Jan 1, 2004 In Use
NA olaparib Lynparza 50 mg Chemotherapy Enzyme Inhibitor PARP Yes 2014 In Use
NA oxymetholone Anadrol-50 50 mg Ancillary Therapy Anabolic Steroid Androgen Yes 1972 In Use
NA sonidegib odozmo 200 mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2015 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
NA Panobinostat Farydak 15 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
J2505 Pegfilgrastim Neulasta:Neulasta Onpro 6 mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2002 Jan 1, 2004 Jan 26, 2022 No Longer Used
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan 1, 2021 In Use
J9207 ixabepilone Ixempra 1mg Chemotherapy Antitumor Antibiotic Epothilones No 2007 Jan 1, 2009 In Use
C9131 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jul 1, 2013 Dec 31, 2013 No Longer Used
NA venetoclax Venclexta 10 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
J9040 Bleomycin Bleomycin 15 units Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1973 Jan 1, 1984 In Use
J0594 Busulfan Busulfex 1 mg Chemotherapy Alkylating Agent Alkylsulfonate No 1999 Jan 1, 2007 In Use
J9043 Cabazitaxel Jevtana 1 mg Chemotherapy Antimitotic Agent Taxane No 2010 Jan 1, 2012 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.